March 30, 2017 2:10 PM ET

Biotechnology

Company Overview of Qiagen Marseille Société Anonyme

Company Overview

QIAGEN Marseille S.A., a molecular diagnosis company, develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia. The company was formerly known as IPSOGEN S.A. and changed its name to QIAGEN Marseille S.A. in January 2013. The company was founded in 1999 and is headquartered in Marseille, France. QIAGEN Marseille S.A. is a subsidiary of HalioDx.

Luminy Biotech Entreprises

Case 923

163 avenue de Luminy

Cedex 9

Marseille,  13288

France

Founded in 1999

74 Employees

Phone:

33 4 91 29 30 90

Fax:

33 4 91 29 30 99

Key Executives for Qiagen Marseille Société Anonyme

Co-Founder and Senior Director of R&D & Regulatory Affairs
Chief Financial Officer
Senior Vice President of Commercial Operations
Vice President of Marketing & Sales for Europe & Asia
Quality Assurance Director
Compensation as of Fiscal Year 2016.

Qiagen Marseille Société Anonyme Key Developments

Qiagen Marseille Société Anonyme(ENXTPA:ALIPS) dropped from Alternext All-Share index

Qiagen Marseille Société Anonyme(ENXTPA:ALIPS) dropped from Alternext All-Share index

QIAGEN Marseille’s Shares To Be Delisted From Alternext Paris

In accordance with Articles 237-14 et seq of the AMF General Regulations, QIAGEN N.V. (offeror) applied to the French Financial Markets Authority (Autorité des Marchés Financiers) (AMF) for the implementation of the mandatory squeeze-out process for the shares of QIAGEN Marseille. The implementation of the mandatory squeeze-out process was approved by the AMF on June 25, 2015 in decision number D&I215C0900. The mandatory squeeze-out will cover all of the shares of QIAGEN Marseille, except the shares of QIAGEN Marseille held by the Offeror and the Assimilated Shares, that is 99,969 shares representing 125,247 voting rights (that is 1.84% of the share capital and 1.20% of the voting rights). The shares of QIAGEN Marseille covered by the mandatory squeeze-out will be transferred to the offeror in return for the payment of a price identical to the price of the offer, EUR 14.90 net of all costs, to their holder. The mandatory squeeze-out will be effective as of June 29, 2015 and the shares of QIAGEN Marseille will be delisted from Alternext Paris on that date.

Similar Private Companies By Industry

Company Name Region
Acticor Biotech SAS Europe
Ademtech SA Europe
Aelis Farma S.A.S. Europe
Aenitis Technologies SAS Europe
Alderys SAS Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Qiagen Marseille Société Anonyme, please visit www.qiagenmarseille.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.